Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘ASH 2014 Immunotherapy’

San Francisco – the 2014 annual meeting of the American Society of Hematology kicks off today. Yesterday was “Super Friday” –  a day when the non-profit and industry sponsored satellite symposia and other ancillary meetings, take center stage.

Each day (Sat – Mon) at the ASH meeting here in San Francisco, we we’ll be sharing information on which sessions we are in. For all those who have asked how do we get a photo with our antibuddies: @gene_antibody, we’ll mention where they are if we see them 🙂

By the way to get a photo you have to be able to identify which one is which – tip: there’s a monoclonal, bispecific, ADC and glycoengineered. Can you work out which is which from the picture? If not, it’s time to brush up on your antibody structures!

In addition, throughout the day (schedule and wifi permitting) we’ll be updating the rolling blog with short comments on the oral sessions and posters we’ve been in and what’s captured our attention. The hematology community has embraced Twitter, with many of the leading experts in the field sharing commentary and insights on their specialized area. ASH is also particularly welcoming to patient advocates who will be live-tweeting too. Expect the #ASH14 Twitter hashtag to generate a lot of information. If you’d like to share the ASH journey with us over the next 3 days, you can purchase access by clicking on the blue icon at the end of the post. Existing subscribers already know how to login. Let the meeting commence!

ASH 2014 annual meeting APP screenSan Francisco – do you want to know the difference between Non-Hodgkin’s Lymphoma and Hodgkin’s Lymphoma? Do you want to know what my top 10 abstracts are in Hodgkin’s Lymphoma and aggressive lymphomas that discuss promising new agents in development? Which of these abstracts should have been a plenary at the meeting?

If the answer is “Yes” to the above, then this blog post is for you!

When I consider what is worthy of a plenary presentation at a meeting like ASH, I think back to the Gleevec phase 1 data presented at ASH in 1999 when I was in Novartis Oncology New Products. It’s data that makes you go WOW!, is transformative or has the potential to change the field. That’s what Gleevec did in CML.

To read the full article, you can sign up or sign in below:

error: Content is protected !!